Cargando…

Pemafibrate Ameliorates Liver Dysfunction and Fatty Liver in Patients with Non-Alcoholic Fatty Liver Disease with Hypertriglyceridemia: A Retrospective Study with the Outcome after a Mid-Term Follow-Up

Non-alcoholic fatty liver disease (NAFLD) is a chronic liver disease related to metabolic syndrome. No standard pharmacological treatment has yet been established. We retrospectively evaluated the efficacy of pemafibrate in 16 NAFLD patients (11 men and 5 women; median age, 59 years; range, 27–81 ye...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ikeda, Suguru, Sugihara, Takaaki, Kihara, Takuya, Matsuki, Yukako, Nagahara, Takakazu, Takata, Tomoaki, Kitao, Sonoko, Okura, Tsuyoshi, Yamamoto, Kazuhiro, Isomoto, Hajime
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8700575/ https://www.ncbi.nlm.nih.gov/pubmed/34943553 http://dx.doi.org/10.3390/diagnostics11122316

Ejemplares similares

Identification and Quantification of Jaundice by Trans-Conjunctiva Optical Imaging Using a Human Brain-like Algorithm: A Cross-Sectional Study
por: Kihara, Takuya, et al.
Publicado: (2023)

COVID-19-Triggered Acute Liver Failure and Rhabdomyolysis: A Case Report and Review of the Literature
por: Matsuki, Yukako, et al.
Publicado: (2023)

The Characteristics and Prognosis of Alpha-Fetoprotein and Des-Gamma-Carboxy Prothrombin Double-Negative Hepatocellular Carcinoma at Baseline in Higher BCLC Stages
por: Nagahara, Takakazu, et al.
Publicado: (2023)

A vein-viewing application enabled detecting abdominal wall varices related to the presence of non-treated gastroesophageal varices: a cross-sectional study
por: Hoshino, Yoshiki, et al.
Publicado: (2021)

Photosensitizer verteporfin inhibits the growth of YAP- and TAZ-dominant gastric cancer cells by suppressing the anti-apoptotic protein Survivin in a light-independent manner
por: Hasegawa, Takashi, et al.
Publicado: (2021)

Pemafibrate improves liver dysfunction and non-invasive surrogates for liver fibrosis in patients with non-alcoholic fatty liver disease with hypertriglyceridemia: a multicenter study
por: Morishita, Asahiro, et al.
Publicado: (2022)

Effect of 48‐week pemafibrate on non‐alcoholic fatty liver disease with hypertriglyceridemia, as evaluated by the FibroScan‐aspartate aminotransferase score
por: Hatanaka, Takeshi, et al.
Publicado: (2021)

Effect of pemafibrate on liver enzymes and shear wave velocity in non-alcoholic fatty liver disease patients
por: Sugimoto, Ryosuke, et al.
Publicado: (2023)

Pemafibrate decreases markers of hepatic inflammation in patients with non-alcoholic fatty liver disease
por: Shinozaki, Satoshi, et al.
Publicado: (2020)

Combination Therapy Using Pemafibrate and Dapagliflozin for Metabolic Dysfunction-associated Fatty Liver Disease
por: Imamura, Teruhiko, et al.
Publicado: (2022)

Impact of Pemafibrate in Patients with Hypertriglyceridemia and Metabolic Dysfunction-associated Fatty Liver Disease Pathologically Diagnosed with Non-alcoholic Steatohepatitis: A Retrospective, Single-arm Study
por: Hatanaka, Takeshi, et al.
Publicado: (2021)

Novel Selective PPARα Modulator Pemafibrate for Dyslipidemia, Nonalcoholic Fatty Liver Disease (NAFLD), and Atherosclerosis †
por: Yamashita, Shizuya, et al.
Publicado: (2023)

Expanding the phenotypic spectrum of non-alcoholic fatty liver disease and hypertriglyceridemia
por: Meroni, Marica, et al.
Publicado: (2022)

Effects of body composition and liver function after long-term pemafibrate treatment on dyslipidemia-associated non-alcoholic fatty liver disease
por: Ishikawa, Toru, et al.
Publicado: (2023)

Pemafibrate therapy for non-alcoholic fatty liver disease is more effective in lean patients than obese patients
por: Shinozaki, Satoshi, et al.
Publicado: (2022)

Combined effect of obesity and uric acid on nonalcoholic fatty liver disease and hypertriglyceridemia
por: Zhang, Shujun, et al.
Publicado: (2017)

5-Aminolevulinic Acid Attenuates Glucose-Regulated Protein 78 Expression and Hepatocyte Lipoapoptosis via Heme Oxygenase-1 Induction
por: Hashimoto, Takaaki, et al.
Publicado: (2021)

Insulin detemir may be less efficacious in patients with nonalcoholic fatty liver disease and hypertriglyceridemia
por: Whyte, Martin, et al.
Publicado: (2015)

Combined effect of obesity and uric acid on nonalcoholic fatty liver disease and hypertriglyceridemia: Erratum
Publicado: (2017)

Pemafibrate improves hepatic inflammation, function and fibrosis in patients with non-alcoholic fatty liver disease: a one-year observational study
por: Shinozaki, Satoshi, et al.
Publicado: (2021)

Half Dose Once-Daily Pemafibrate Effectively Improved Hypertriglyceridemia in Real Practice
por: Iitake, Chie, et al.
Publicado: (2019)

A Significant Effect of Pemafibrate on Hepatic Steatosis and Fibrosis Indexes in Patients With Hypertriglyceridemia
por: Katsuyama, Hisayuki, et al.
Publicado: (2023)

Is Hepatocellular Carcinoma in Fatty Liver Different to Non-Fatty Liver?
por: Nguyen, Xuan-vinh Kevin, et al.
Publicado: (2022)

Serum miR-379 expression is related to the development and progression of hypercholesterolemia in non-alcoholic fatty liver disease
por: Okamoto, Kinya, et al.
Publicado: (2020)

Preferable effects of pemafibrate on liver function and fibrosis in subjects with type 2 diabetes complicated with liver damage
por: Nomoto, Hiroshi, et al.
Publicado: (2023)

Pemafibrate Protects against Fatty Acid-Induced Nephropathy by Maintaining Renal Fatty Acid Metabolism
por: Aomura, Daiki, et al.
Publicado: (2021)

Efficacy and Safety of Low-Dose Pemafibrate Therapy for Hypertriglyceridemia in Patients with Type 2 Diabetes
por: Bando, Hidenori, et al.
Publicado: (2021)

Apolipoprotein CIII Overexpression-Induced Hypertriglyceridemia Increases Nonalcoholic Fatty Liver Disease in Association with Inflammation and Cell Death
por: Paiva, Adriene A., et al.
Publicado: (2017)

SAT-088 A Novel Mutation In The Leptin Receptor Associated With Hypertriglyceridemia, Lipodystrophy And Non-alcoholic Fatty Liver
por: Viana, Gracia, et al.
Publicado: (2019)

Fatty liver in children
por: Rafeey, Mandana, et al.
Publicado: (2009)

Liver fatty acid composition in mice with or without nonalcoholic fatty liver disease
por: Wang, Xin, et al.
Publicado: (2011)

Precision Medicine in Fatty Liver Disease/Non-Alcoholic Fatty Liver Disease
por: Valenzuela-Vallejo, Laura, et al.
Publicado: (2023)

Diabetes and fatty liver: Involvement of incretin and its benefit for fatty liver management
por: Wibawa, I Dewa Nyoman, et al.
Publicado: (2023)

Steatosis is involved in the progression of kidney disease in a high-fat-diet-induced non-alcoholic steatohepatitis mouse model
por: Hamada, Shintaro, et al.
Publicado: (2022)

Efficacy and Safety of Pemafibrate Versus Bezafibrate to Treat Patients with Hypertriglyceridemia: A Randomized Crossover Study
por: Nakamura, Akihiro, et al.
Publicado: (2023)

Efficacy and Safety of Pemafibrate Versus Bezafibrate to Treat Patients with Hypertriglyceridemia: A Randomized Crossover Study
por: Nakamura, Akihiro, et al.
Publicado: (2023)

Fluorescence Imaging Using Enzyme-Activatable Probes for Detecting Diabetic Kidney Disease and Glomerular Diseases
por: Yamada, Kentaro, et al.
Publicado: (2022)

Liver fibrosis is associated with carotid atherosclerosis in patients with liver biopsy-proven nonalcoholic fatty liver disease
por: Arai, Taeang, et al.
Publicado: (2021)

Non-alcoholic fatty liver disease, to struggle with the strangle: Oxygen availability in fatty livers
por: Anavi, Sarit, et al.
Publicado: (2017)

Fatty Liver Index for Predicting Nonalcoholic Fatty Liver Disease in an Asymptomatic Korean Population
por: Cho, Eun-Ju, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_k4hske6h76q80713gd66fg3n7r